← Leaderboards
Nicholas George Nickols
Va Greater Los Angeles Healthcare System
$0
Attributed
$0
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2015–25$1$1$1$0$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
VA$0 · 4
By mechanism
I01$0 · 3
IK2$0 · 1
Top collaborators
- Matthew B Rettig4 shared
- Isla Pearl Garraway2 shared
- Beatrice S Knudsen2 shared
- Anant Madabhushi2 shared
- Rudolph C Johnson1 shared
Others in their field
Top investigators on “Diagnosis”
- David Heimbrook · Leidos Biomedical Research, Inc.$590,717,255
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$337,858,596
- Richard K. Wilson · Washington University$297,645,172
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
Research focus
DiagnosisVeteransMalignant Neoplasm Of ProstateGenomicsMalignant NeoplasmsAmericanBiologyAbirateroneCancer DiagnosisNeoplasm MetastasisCessation Of LifeMaleTumorCharacteristicsMutationProstatic NeoplasmsLesionPreventOperative Surgical ProceduresPalliationPalliativeCancer EtiologyMetastatic Prostate CancerImproved Outcome
Grant awards (13)
Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)$0
I01 · FY2025 · VA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2024 · VA
Phase II Trial of targeted Radiation with no castration for mcrpc (POTENT-C)$0
I01 · FY2024 · VA · contact PI
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2023 · VA · contact PI
Predicting Metastatic Progression of High Risk Localized Prostate Cancer$0
I01 · FY2023 · VA
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2022 · VA · contact PI
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2021 · VA · contact PI
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2020 · VA · contact PI
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2019 · VA · contact PI
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer$0
I01 · FY2018 · VA · contact PI
Programmable DNA-binders as radio-modulators and therapeutics for prostate cancer$0
IK2 · FY2017 · VA · contact PI
Programmable DNA-binders as radio-modulators and therapeutics for prostate cancer$0
IK2 · FY2016 · VA · contact PI
Programmable DNA-binders as radio-modulators and therapeutics for prostate cancer$0
IK2 · FY2015 · VA · contact PI